- Home
- AVTX vs VTGN Comparison
AVTX vs VTGN Comparison
Compare AVTX & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | VTGN |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 21.8M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AVTX | VTGN |
|---|---|---|
| Price | $17.76 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $36.80 | $0.90 |
| AVG Volume (30 Days) | ★ 805.9K | 417.5K |
| Earning Date | 05-11-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | N/A | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $0.43 |
| 52 Week High | $20.72 | $5.14 |
Technical Indicators
Market Signals| Indicator | AVTX | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.28 | 45.48 |
| Support Level | $17.18 | $0.57 |
| Resistance Level | $19.26 | $0.60 |
| Average True Range (ATR) | 1.20 | 0.04 |
| MACD | 0.28 | 0.00 |
| Stochastic Oscillator | 98.63 | 35.85 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.